BMS-852927 (also known as XL041) is a partial agonist of LXRβ (liver X receptor β).

Abequolixron (formerly known as SB742881; RG104; SB-742881) is a novel potent and orally bioavailable liver-X nuclear hormone receptor-beta (LXR) agonist with potential immunomodulating and anticancer activities.

LXR623 (WAY-252623; LXR-623) is a novel, highly brain-penetrant, selective and orally bioavailable synthetic modulator of LXR (Liver X receptor) with anticancer activity, It is a partial LXRα and full LXRβ agonist with IC50s of 24 nM and 179 nM, respectively.

GW3965 (GW-3965) is a novel, potent, selective LXR (liver X receptor) agonist for hLXRα and hLXRβ with anti-inflammatory effects.

AZ-876 is a novel, potent high-affinity agonist of Liver X Receptor (LXR) with Ki values of 0.007 μM and 0.011 μM for human LXRα and LXRβ respectively.

SR9243 (SR-9243) is a potent and selective inverse agonist of LXR.

Abequolixron HCl (formerly RGX-104; SB-742881; SB742881), the hydrochloride salt of RGX104, is a novel potent and orally bioavailable liver-X nuclear hormone receptor-beta (LXR) agonist that modulates innate immunity via transcriptional activation of the ApoE gene.

GW3965 (GW-3965) HCl, the hydrochloride salt of GW3965, is a novel, potent, selective LXR (liver X receptor) agonist for hLXRα and hLXRβ with potential anti-inflammatory activity.

BMS-779788 (formerly known as XL-652, EXEL 04286652 and BMS-788) is a novel and potent LXR (Liver X Receptors) partial agonist with IC50 values of 68 nM for LXRα and 14 nM for LXRβ.

GSK2033 is a novel, potent and cell-active LXR (liver X receptor) antagonist with pIC50s of 7 and 7.4 for LXRα or LXRβ.